Have your say! Survey on drug-resistant TB treatment options

In December 2017, Treatment Action Group (TAG), ACTION and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) conducted a webinar on the results of two phase III trials for treating rifampicin-resistant TB.

One suggestion that came out of the webinar was to poll people working in and affected by TB about which treatment regimen they would want, if diagnosed with rifampicin-resistant TB.

Please take a moment to reflect and answer this question here: https://www.surveymonkey.com/r/2QQ3F32 

Please complete this short survey by 20 February 2018!

To subscribe to the Weekly Newsletter of new posts, enter your email here:


By Treatment Action Group

Published: Jan. 26, 2018, 12:32 a.m.

Last updated: Feb. 3, 2018, 12:51 p.m.

Print Share